ideasIdea
A breath test to rule out cancer in people with vague symptoms
Volatile compounds in breath differ in cancer. A breath test validated in truly symptomatic patients, not lab volunteers, could tell GPs who needs urgent scans and who can safely wait.
Breath VOC studies are mostly case-control and fail on replication. Propose validation exclusively in prospective symptomatic primary-care cohorts, targeting a rule-out use (negative predictive value above 99%) rather than diagnosis, with locked classifiers and external validation before any clinical use.
Hypothesis
A breath VOC panel achieves at least 99% NPV for any cancer within 12 months in symptomatic patients aged 50 and over, allowing safe deferral of imaging in at least 40% of referrals.
Rationale
The rule-out use case tolerates imperfect specificity and matches the actual clinical bottleneck, which is imaging capacity.
What would test it
5,000-patient prospective cohort through Rapid Diagnostic Centres with a pre-registered analysis plan.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks
- Most lethal cancers are found late · Screening exists for only a few cancers. Pancreatic, ovarian, liver, oesophageal and most lung cancers are found when cure is unlikely.
- Biomarkers are not validated or standardised · Tests that decide who gets a drug are often not validated prospectively and are measured differently in every lab.